CRAC Channel Modulators for Selective Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and inflammatory conditions often rely on non-specific immunosuppressive therapies, which can have significant side effects and do not directly target the underlying calcium-mediated immune responses.
Innovation Solution
Development of compounds, such as those represented by Formulas (I), (II), (III), and (IV), that selectively inhibit store-operated calcium (SOC) channel activity, particularly CRAC channel activity, to modulate intracellular calcium levels and reduce immune cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunosuppressive therapies are used to treat autoimmune diseases and inflammatory conditions, then immune response is suppressed, but side effects increase and selectivity decreases
Solution Approach 1:
The invention segments the immune response pathway by specifically targeting the CRAC channel-mediated calcium influx mechanism. Instead of using broad immunosuppressants that affect multiple immune pathways, the compounds selectively inhibit store-operated calcium entry through CRAC channels, thereby suppressing pathogenic immune responses while preserving other essential immune functions. This segmentation approach reduces off-target effects and improves therapeutic selectivity.
2Reliability
If non-specific immunosuppressive therapies are used, then immune response is suppressed, but selectivity decreases
Solution Approach 1:
The invention applies local quality by designing compounds that specifically target the CRAC channel protein structure and its interaction with STIM proteins. The compounds exhibit selective binding to CRAC channels, producing localized inhibition of calcium-mediated immune activation in specific cell types (such as T cells and mast cells) while leaving other calcium channels and immune pathways unaffected. This localized specificity achieves both effectiveness and selectivity.
3Object-generated harmful factors
If store-operated calcium channel activity is inhibited to reduce immune cell activation, then cytokine release decreases, but mechanism complexity increases
Solution Approach 1:
The invention extracts and isolates the critical pathogenic step in immune activation by specifically blocking CRAC channel-mediated calcium influx. By taking out this single essential step (calcium entry through CRAC channels) from the complex immune activation cascade, the compounds effectively prevent downstream cytokine release and immune cell activation. This focused extraction simplifies the therapeutic mechanism compared to broad immunosuppression, even though the molecular target (CRAC channel) is specific.
Data Source
AI summary
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.